Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma

Crombie, Jennifer; Nastoupil, Loretta J.; Redd, Robert A.; Tang, Kevin; Shouse, Geoffrey; Herrera, Alex F.; Chow, Victor A.; Shadman, Mazyar; Puglianini, Omar Castaneda; Saucier, Anna; Jacobson, Caron A.; Armand, Philippe; Simmons, Gary

doi:10.1182/bloodadvances.2021004880

Cited by 11 publications

(16 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of non‐haematological toxicities of axi‐cel (CRS and ICANS) was comparable to other real‐world experiences with axi‐cel 18,19 . We did not find a statistical association between BT and higher incidence of ICANS, even if we did observe a higher incidence of ICANS among the patients who received BT (55.9%) compared with the patients who did not (46.1%, data not shown), as other authors have previously described 20 …”

Section: Discussionsupporting

confidence: 82%

Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study

Iovino

Voutsinas

et al. 2022

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 82%

Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study

Iovino

Voutsinas

et al. 2022

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similarly to tisagenlecleucel, axicabtagene ciloleucel is composed of bulk T cells of unspecified CD4(+) to CD8(+) ratio [ 22 ]. Average ORR for DLBCL is 75%, for FL 81% [ 19 ], while for PMBL 80–73% depending of the type of patients’ pre-treatment [ 21 , 25 ]. CRR values were 52% for DLBCL, 64% for FL [ 19 ] and 72–54% for PMBL [ 21 , 25 ].…”

Section: Car-t Cells Approved For Clinical Practice In the European U...mentioning

confidence: 99%

“…Average ORR for DLBCL is 75%, for FL 81% [ 19 ], while for PMBL 80–73% depending of the type of patients’ pre-treatment [ 21 , 25 ]. CRR values were 52% for DLBCL, 64% for FL [ 19 ] and 72–54% for PMBL [ 21 , 25 ]. In a small study including three patients, Baras et al [ 26 ] demonstrated the presence of axicabtagene ciloleucel CAR-T cells in patients’ blood up to 300 days post-infusion, as measured by both flow cytometry and quantitative PCR.…”

Section: Car-t Cells Approved For Clinical Practice In the European U...mentioning

confidence: 99%

Current and Future Perspectives for Chimeric Antigen Receptor T Cells Development in Poland

et al. 2022

View full text Add to dashboard Cite

Chimeric antigen receptor T (CAR-T) cells are genetically modified autologous T cells that have revolutionized the treatment of relapsing and refractory haematological malignancies. In this review we present molecular pathways involved in the activation of CAR-T cells, describe in details the structures of receptors and the biological activity of CAR-T cells currently approved for clinical practice in the European Union, and explain the functional differences between them. Finally, we present the potential for the development of CAR-T cells in Poland, as well as indicate the possible directions of future research in this area, including novel modifications and applications of CAR-T cells and CAR-natural killer (NK) cells.

show abstract

“…However, only eight patients with PMBCL were included in this pivotal trial; at a median follow-up of 27 months, ongoing responses were maintained in five of eight cases [ 14 ]. There are only two real-world retrospective experiences, one reporting the outcome of 33 patients treated with axi-cel in United States, with ORR 78% and 69% CR, and 2-year PFS and OS 64% (95% CI: 49–84) and 78% (95% CI: 64–96), respectively [ 16 ]; the second one, is a retrospective sub-analysis of the German registry, reporting the outcome of 13 PMBCL with 2‐year PFS and OS of 54% and 75% [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study

Chiappella,

Casadei,

Chiusolo

et al. 2024

Leukemia

View full text Add to dashboard Cite

Axicabtagene ciloleucel showed efficacy for relapsed/refractory large B-cell lymphomas (LBCL), including primary mediastinal B-cell lymphomas (PMBCL); however, only few PMBCLs were reported. Aim was to evaluate efficacy and safety of axicabtagene ciloleucel in patients with PMBCL compared to those with other LBCL, enrolled in the Italian prospective observational CART-SIE study. PMBCLs (n = 70) were younger, with higher percentage of bulky and refractory disease, compared to other LBCLs (n = 190). Median follow-up time for infused patients was 12.17 months (IQR 5.53,22.73). The overall (complete + partial) response rate (ORR,CR + PR) after bridging was 41% for PMBCL and 28% for other LBCL, p = 0.0102. Thirty days ORR was 78% (53/68) with 50% (34) CR in PMBCL, and 75% (141/187) with 53% (100) CR in other LBCL, p = 0.5457. Ninety days ORR was 69% (45/65) with 65% (42) CR in PMBCL, and 54% (87/162) with 47% (76) CR in other LBCL; progressive disease was 21% in PMBCL and 45% in other LBCL, p = 0.0336. Twelve months progression-free survival was 62% (95% CI: 51–75) in PMBCL versus 48% (95% CI: 41–57) in other LBCL, p = 0.0386. Twelve months overall survival was 86% (95% CI: 78–95) in PMBCL versus 71% (95% CI: 64–79) in other LBCL, p = 0.0034. All grade cytokine release syndrome was 88% (228/260); all grade neurotoxicity was 34% (88/260), with 6% of fatal events in PMBCL. Non-relapse mortality was 3%. In conclusion, PMBCLs achieved significantly better response and survival rates than other LBCLs.

show abstract

Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma

Cited by 11 publications

References 16 publications

Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study

Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study

Current and Future Perspectives for Chimeric Antigen Receptor T Cells Development in Poland

Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study

Contact Info

Product

Resources

About